Skip to main content
Erschienen in:

28.06.2020 | Original Article

The prognostic relevance of primary tumor sidedness to surgical treatment for recurrent colon cancer

verfasst von: Tairin Uchino, Akira Ouchi, Koji Komori, Takashi Kinoshita, Taihei Oshiro, Tsuyoshi Sano, Yasuhiro Shimizu

Erschienen in: Surgery Today | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to investigate the predictive relevance of tumor sidedness on surgical resection after recurrence by evaluating the treatment outcomes after primary resection and recurrence in patients with localized colon cancer (CC).

Methods

A total of 735 consecutive patients who underwent curative resection for Stage I–III CC from 1997 to 2013 were categorized as having either right- or left-sided CC, and survival after primary surgery and after recurrence were analyzed.

Results

A total of 104 patients (14.1%) developed recurrence, 94 of which were in a single organ, and 59 patients underwent curative resection. For recurrence from both sides of the colon, a significantly better 5-year overall survival (OS) was experienced by patients who underwent curative resection compared to those who received palliative treatment (right: 42.2% vs not reached, respectively; P < 0.001; left: 71 vs 15.9%, respectively; P < 0.001). Meanwhile, a still worse OS was observed in patients with curative resection for recurrent right-sided CC compared to those with resection for recurrent left-sided CC (5-year: 42.2 vs 71%; P = 0.03).

Conclusion

Surgical resection undoubtedly improved survival after recurrence, however, patients with surgical resection for recurrent right-sided CC tended to have a worse prognosis.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–386.PubMedCrossRef Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–386.PubMedCrossRef
2.
Zurück zum Zitat Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet (London, England). 2014;383(9927):1490–502.CrossRef Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet (London, England). 2014;383(9927):1490–502.CrossRef
3.
Zurück zum Zitat Taieb J, Kourie HR, Emile JF, Le Malicot K, Balogoun R, Tabernero J, et al. Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status. JAMA Oncol. 2018;4(7):e173695.PubMedCrossRef Taieb J, Kourie HR, Emile JF, Le Malicot K, Balogoun R, Tabernero J, et al. Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status. JAMA Oncol. 2018;4(7):e173695.PubMedCrossRef
4.
Zurück zum Zitat Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2016. Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2016.
5.
Zurück zum Zitat Shen H, Yang J, Huang Q, Jiang MJ, Tan YN, Fu JF, et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol. 2015;21(21):6470–8.PubMedPubMedCentralCrossRef Shen H, Yang J, Huang Q, Jiang MJ, Tan YN, Fu JF, et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol. 2015;21(21):6470–8.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O'Neil BH, et al. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34(15_suppl):3504–3504.CrossRef Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O'Neil BH, et al. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34(15_suppl):3504–3504.CrossRef
7.
Zurück zum Zitat Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3(2):194–201.PubMedPubMedCentralCrossRef Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3(2):194–201.PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. Journal of the National Cancer Institute 2015;107(3). Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. Journal of the National Cancer Institute 2015;107(3).
9.
Zurück zum Zitat Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713–29.PubMedPubMedCentralCrossRef Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713–29.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Yamashita S, Brudvik KW, Kopetz SE, Maru D, Clarke CN, Passot G, et al. Embryonic origin of primary colon cancer predicts pathologic response and survival in patients undergoing resection for colon cancer liver metastases. Ann Surg. 2018;267(3):514–20.PubMedCrossRef Yamashita S, Brudvik KW, Kopetz SE, Maru D, Clarke CN, Passot G, et al. Embryonic origin of primary colon cancer predicts pathologic response and survival in patients undergoing resection for colon cancer liver metastases. Ann Surg. 2018;267(3):514–20.PubMedCrossRef
11.
Zurück zum Zitat Gasser E, Braunwarth E, Riedmann M, Cardini B, Fadinger N, Presl J, et al. Primary tumour location affects survival after resection of colorectal liver metastases: a two-institutional cohort study with international validation, systematic meta-analysis and a clinical risk score. PLoS ONE. 2019;14(5):e0217411.PubMedPubMedCentralCrossRef Gasser E, Braunwarth E, Riedmann M, Cardini B, Fadinger N, Presl J, et al. Primary tumour location affects survival after resection of colorectal liver metastases: a two-institutional cohort study with international validation, systematic meta-analysis and a clinical risk score. PLoS ONE. 2019;14(5):e0217411.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Wang Z, Wang X, Zhang Z, Wang X, Chen M, Lu L, et al. Association between primary tumor location and prognostic survival in synchronous colorectal liver metastases after surgical treatment: a retrospective analysis of SEER data. J Cancer. 2019;10(7):1593–600.PubMedPubMedCentralCrossRef Wang Z, Wang X, Zhang Z, Wang X, Chen M, Lu L, et al. Association between primary tumor location and prognostic survival in synchronous colorectal liver metastases after surgical treatment: a retrospective analysis of SEER data. J Cancer. 2019;10(7):1593–600.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Moritani K, Hasegawa H, Okabayashi K, Ishii Y, Endo T, Kitagawa Y. Difference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution. Surg Today. 2014;44(9):1685–91.PubMedCrossRef Moritani K, Hasegawa H, Okabayashi K, Ishii Y, Endo T, Kitagawa Y. Difference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution. Surg Today. 2014;44(9):1685–91.PubMedCrossRef
17.
Zurück zum Zitat Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet (London, England). 2008;371(9617):1007–166.CrossRef Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet (London, England). 2008;371(9617):1007–166.CrossRef
18.
Zurück zum Zitat Yagi K, Takahashi H, Akagi K, Matsusaka K, Seto Y, Aburatani H, et al. Intermediate methylation epigenotype and its correlation to KRAS mutation in conventional colorectal adenoma. Am J Pathol. 2012;180(2):616–25.PubMedCrossRef Yagi K, Takahashi H, Akagi K, Matsusaka K, Seto Y, Aburatani H, et al. Intermediate methylation epigenotype and its correlation to KRAS mutation in conventional colorectal adenoma. Am J Pathol. 2012;180(2):616–25.PubMedCrossRef
19.
Zurück zum Zitat Yagi K, Akagi K, Hayashi H, Nagae G, Tsuji S, Isagawa T, et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res. 2010;16(1):21–33.PubMedCrossRef Yagi K, Akagi K, Hayashi H, Nagae G, Tsuji S, Isagawa T, et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res. 2010;16(1):21–33.PubMedCrossRef
20.
Zurück zum Zitat Sakai E, Fukuyo M, Ohata K, Matsusaka K, Doi N, Mano Y, et al. Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway. Int J Cancer. 2016;138(7):1634–44.PubMedCrossRef Sakai E, Fukuyo M, Ohata K, Matsusaka K, Doi N, Mano Y, et al. Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway. Int J Cancer. 2016;138(7):1634–44.PubMedCrossRef
Metadaten
Titel
The prognostic relevance of primary tumor sidedness to surgical treatment for recurrent colon cancer
verfasst von
Tairin Uchino
Akira Ouchi
Koji Komori
Takashi Kinoshita
Taihei Oshiro
Tsuyoshi Sano
Yasuhiro Shimizu
Publikationsdatum
28.06.2020
Verlag
Springer Singapore
Erschienen in
Surgery Today / Ausgabe 1/2021
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-020-02060-0

Neu im Fachgebiet Chirurgie

Welcher Zugangsweg ist besser für den interventionellen Mitralklappenersatz?

Bisher wird für den interventionellen Mitralklappenersatz standardmäßig der transapikale Zugangsweg gewählt. In einer Registeranalyse hat dieser in puncto Sicherheit allerdings den Kürzeren gezogen.

Lohnt sich die Karotis-Revaskularisation?

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Höhere Dosis von Dexamethason senkt Überlebenschancen

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

Appendektomie erhält Remission bei Colitis ulcerosa

Wird der Wurmfortsatz bei Personen mit Colitis ulcerosa entfernt, ist die Rückfallrate um ein Drittel geringer als unter konservativer Behandlung. Auch die Lebensqualität verbessert sich und der Bedarf an Medikamenten nimmt ab.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.